VP of commercial strategy and innovation at Innomar, explains how handling uncertainty comes down to discipline. Advertisement. Latest Updated Articles ...
In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski, vice president, strategic market ...
Pharmaceutical Executive: How are US regulatory actions impacting pricing? Dr. Stella Vnook: I'm still trying to reconcile ...
In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, situates the Strait of ...
In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...
As a variety of issues continue to impact the global supply chain, pharmaceutical and biotech companies must plan for ...
In a conversation with Pharmaceutical Executive at Asembia’s AXS26 Summit, Kim Plesnarski vice president, strategic market ...
At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more ...
FDA approves Breztri Aerosphere for asthma, introducing the first single-inhaler triple-combination maintenance therapy for ...
Sun Pharma will pay $14.00 per share cash for Organon, targeting early-2027 close subject to regulatory and shareholder ...
The most important issue the industry faces is healthcare and drug pricing. With 2026 being a key election year, regulators ...
In today's Pharmaceutical Executive Daily, we cover Sun Pharma and IMG Pharma's respective acquisitions, FDA's approval of AstraZeneca's Breztri, and a new feature examining why Ireland has become one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results